Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. MDBH
MDBH logo

MDBH Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
3.550
Open
3.500
VWAP
3.48
Vol
4.07K
Mkt Cap
36.54M
Low
3.400
Amount
14.17K
EV/EBITDA(TTM)
--
Total Shares
10.44M
EV
21.40M
EV/OCF(TTM)
--
P/S(TTM)
8.00
MDB Capital Holdings, LLC is a holding company that has three subsidiaries: MDB CG Management Company (MDB Management), Public Ventures, LLC (Public Ventures), and PatentVest, Inc. (PatentVest), and has a partner company, MDB Minnesota One, Inc. Its segments include broker dealer & intellectual property service, and technology development. The broker dealer & intellectual property service segment has two subsidiaries, Public Ventures and PatentVest. Public Ventures is a full-service broker dealer firm focusing on conducting private and public securities offerings. PatentVest offers in-depth patent research used for investment banking due diligence. The technology development segment includes MDB Minnesota One, Inc., a research and development stage company that is developing a small molecule senescence platform. MDB Management is an administrative entity whose purpose is to conduct, and wherever possible, to consolidate shared services/resources, for its United States-based operations.
Show More

Events Timeline

(ET)
2025-06-02
17:54:11
MDB Capital announces board transitions
select
2025-05-27 (ET)
2025-05-27
16:12:20
ClearSign Board to expand in size to seven directors
select
2025-05-21 (ET)
2025-05-21
09:04:20
MDB Capital provides Q1 update, continued to work on new opportunities
select
2025-02-21 (ET)
2025-02-21
16:07:58
eXoZymes president, chairman Hayat transitions out of roles
select

News

Newsfilter
7.5
05-08Newsfilter
Analysis of Global Triple-Agonist Drug Market
  • Competitive Landscape: PatentVest's report highlights that industry leaders such as Eli Lilly, Novo Nordisk, Pfizer, Roche, and Sanofi, along with emerging players like Hanmi Pharmaceutical and Innovent Biologics, are fiercely competing to dominate the next generation of obesity therapeutics, indicating an intensifying competitive environment.
  • Global Pipeline Expansion: The report identifies 27 triple-agonist programs, with China playing a significant role in development activities, signaling a shift in global innovation dynamics and potential future licensing opportunities in the obesity drug market.
  • Intellectual Property Dynamics: Patent analysis reveals a transition in competitive advantage drivers from receptor discovery to receptor-ratio engineering, formulation control, delivery systems, and method-of-use claims, underscoring the critical role of intellectual property in shaping future market landscapes.
  • Strategic Positioning: Findings suggest that companies like Sanofi, despite lacking visible clinical programs, may possess significant latent IP positions that could influence the future market structure, emphasizing the strategic importance of controlling intellectual property.
Newsfilter
5.0
04-29Newsfilter
Eli Lilly's Retatrutide Redefines Weight Loss Market
  • Weight Loss Breakthrough: Eli Lilly's retatrutide achieved a mean weight loss of 28.7% in April 2026, becoming the first non-surgical therapy to match bariatric outcomes, marking a significant advancement in weight loss treatment.
  • Intensified Market Competition: Following the success of retatrutide, companies like Novo Nordisk, Pfizer, and Hanmi are ramping up their R&D efforts to capture market share, highlighting the industry's keen focus on controlling intellectual property.
  • Intellectual Property Strategy: PatentVest emphasizes that the future competition will pivot towards who can effectively manage IP and who can secure market advantages, underscoring the critical role of intellectual property in drug development.
  • Clinical Results vs. Real-World Outcomes: Despite the impressive 28.7% weight loss in clinical trials, PatentVest warns of potential discrepancies in real-world effectiveness, suggesting that future competition will center on bridging this gap.
Yahoo Finance
9.5
04-07Yahoo Finance
MDB Capital Holdings Earnings Outlook
  • Proven IPO Model: MDB Capital Holdings LLC (NASDAQ:MDBH) has successfully launched 18 IPOs, demonstrating its strong capabilities in the microcap market, although the current market conditions are challenging, its model still holds potential to attract investors.
  • AI-Driven Due Diligence: The company is leveraging artificial intelligence to potentially reduce due diligence and company preparation time by two-thirds, which not only enhances efficiency but may also accelerate the launch of new companies, thereby diversifying and increasing the potential returns of its investment portfolio.
  • Investment in Distinct Assets: MDBH is investing in unique assets like MDB Direct and PatentVest, which possess independent market value and are expected to achieve higher valuations through spin-offs, further enhancing the company's overall financial performance.
  • Macroeconomic Uncertainty: Despite the company's advantages in assets and technology, uncertainties in the macroeconomic environment and internal execution risks could impact its future business development and investment returns, necessitating vigilance from investors.
seekingalpha
9.5
03-31seekingalpha
MDB Capital Holdings FY 2025 Operating Expense Overview
  • Annual Operating Expenses: MDB Capital Holdings reported fixed operating expenses of approximately $10 million for FY 2025, which includes a $4 million investment in the MDB Direct/Public Ventures clearing platform, indicating a commitment to enhancing its technological infrastructure.
  • Cash Position: At year-end, the company held approximately $22.3 million in cash, current assets, and marketable securities after liabilities, reflecting strong financial health and effective liquidity management.
  • Investment Expenditure: The cash used for PatentVest.Net in FY 2025 was approximately $5.7 million, showcasing the company's strategic focus on intellectual property management and related technologies to bolster its competitive edge in the market.
  • Financial Health: MDB Capital Holdings' financial data indicates that despite fixed operating expenses and investment outlays, the company maintains a solid cash reserve, positioning itself well for future business growth and investment opportunities.
Newsfilter
7.5
03-31Newsfilter
Amylin Drug Market New Opportunities
  • Surge in Market Investment: Over the past 18 months, more than $19 billion in deal value has been committed in the amylin space, with major pharmaceutical companies like Novo Nordisk, Eli Lilly, Roche, Pfizer, and AbbVie actively positioning themselves, indicating strong confidence in the obesity drug market.
  • Rich R&D Pipeline: Nearly 40 amylin receptor agonist programs are currently in development worldwide, with the first GLP-1/amylin combination therapy approaching FDA decision, signaling significant market potential.
  • Significant Efficacy: Clinical data demonstrates that amylin-based therapies can achieve over 20% weight loss, further enhancing their competitiveness in obesity treatment and attracting increased investor interest.
  • Importance of Patent Strategy: Patent strategy plays a critical role in determining long-term competitive advantage, as noted by PatentVest's Chief IP Officer Will Rosellini, who emphasizes that future winners will be those with sophisticated intellectual property architecture, not just the best molecules.
Newsfilter
2.0
03-30Newsfilter
PatentVest Launches IP Legal Insights Platform for Innovators
  • IP Legal Insights Platform: PatentVest has launched a new IP Legal Insights section aimed at providing founders, executives, and investors with expert analysis on how intellectual property decisions impact innovation and competitive positioning, thereby enhancing long-term business value.
  • AI Patent Application Guidance: The latest article explores the patent application process for AI-assisted inventions, emphasizing key considerations such as patent eligibility, inventorship challenges, and effective prosecution strategies to help companies navigate the complex legal landscape.
  • Technological Improvements and Applications: The article highlights that patentability often depends on claiming strategies, including demonstrating technological improvements and practical applications, while emphasizing the human contribution to the inventive process to ensure legal protection for AI-driven innovations.
  • Industry Trend Analysis: PatentVest's legal and technical experts provide analysis on key patent law developments and emerging trends in industries such as biotechnology, healthcare, and artificial intelligence, assisting companies in maintaining a competitive edge in rapidly changing markets.

Valuation Metrics

The current forward P/E ratio for MDB Capital Holdings LLC (MDBH.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess MDB Capital Holdings LLC's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

con rentabilidad alta a corto plazo
Intellectia · 61 candidates
Price: <= $20.00Quarter Revenue Yoy Growth: >= 20.0%Quarter Eps Yoy Growth: >= 15.0%Relative Vol: >= 1.50
Ticker
Name
Market Cap$
top bottom
RBKB logo
RBKB
Rhinebeck Bancorp Inc
134.53M
BZAI logo
BZAI
Blaize Holdings Inc
255.60M
XLO logo
XLO
Xilio Therapeutics Inc
40.33M
LXRX logo
LXRX
Lexicon Pharmaceuticals Inc
566.90M
IBRX logo
IBRX
Immunitybio Inc
6.82B
MDBH logo
MDBH
MDB Capital Holdings LLC
33.86M

Whales Holding MDBH

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is MDB Capital Holdings LLC (MDBH) stock price today?

The current price of MDBH is 3.5 USD — it has decreased -2.78

What is MDB Capital Holdings LLC (MDBH)'s business?

MDB Capital Holdings, LLC is a holding company that has three subsidiaries: MDB CG Management Company (MDB Management), Public Ventures, LLC (Public Ventures), and PatentVest, Inc. (PatentVest), and has a partner company, MDB Minnesota One, Inc. Its segments include broker dealer & intellectual property service, and technology development. The broker dealer & intellectual property service segment has two subsidiaries, Public Ventures and PatentVest. Public Ventures is a full-service broker dealer firm focusing on conducting private and public securities offerings. PatentVest offers in-depth patent research used for investment banking due diligence. The technology development segment includes MDB Minnesota One, Inc., a research and development stage company that is developing a small molecule senescence platform. MDB Management is an administrative entity whose purpose is to conduct, and wherever possible, to consolidate shared services/resources, for its United States-based operations.

What is the price predicton of MDBH Stock?

Wall Street analysts forecast MDBH stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDBH is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is MDB Capital Holdings LLC (MDBH)'s revenue for the last quarter?

MDB Capital Holdings LLC revenue for the last quarter amounts to 44.00K USD, decreased -94.69

What is MDB Capital Holdings LLC (MDBH)'s earnings per share (EPS) for the last quarter?

MDB Capital Holdings LLC. EPS for the last quarter amounts to -0.66 USD, decreased -0.00

How many employees does MDB Capital Holdings LLC (MDBH). have?

MDB Capital Holdings LLC (MDBH) has 14 emplpoyees as of June 02 2026.

What is MDB Capital Holdings LLC (MDBH) market cap?

Today MDBH has the market capitalization of 36.54M USD.